Replies to post #251742 on Biotech Values

[Fred Kadiddlehopper]

In your estimation, what has caused the downturn in interest in MASH?

[DewDiligence]

More on MDGL’s Rezdiffra launch:

https://www.fiercepharma.com/pharma/remarkable-interest-madrigal-touts-early-launch-progress-first-mash-drug-rezdiffra-despite

In one launch setback, the Veterans Affairs Department has implemented an extra hurdle, requiring a diagnosis from a liver biopsy for a patient to be eligible for Rezdiffra…

MDGL says commercial insurers will not follow suit. We’ll soon see.